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Summary Introduction
Hereditary multiple exostoses (HME), the most frequent Hereditary multiple exostoses (HME), or diaphyseal
of all skeletal dysplasias, is an autosomal dominant dis- aclasis (MIM 133700 and 133701), is an autosomal
order characterized by the presence of multiple exosto- dominant disorder characterized by the presence of mul-
ses localized mainly at the end of long bones. HME is tiple exostoses (osteochondromas) localized mainly in
genetically heterogeneous, with at least three loci, on the juxtaepiphyseal region of long bones. HME is the
8q24.1 (EXT1), 11p11-p13 (EXT2), and 19p (EXT3). most common of all skeletal dysplasias, with estimates
Both the EXT1 and EXT2 genes have been cloned re- of prevalence ranging from 1.3/100,000 (Hennekam
cently and deﬁne a new family of potential tumor sup- 1991) to 2/100,000 cases in a population (Schmale et
pressor genes. This is the ﬁrst study in which mutation al. 1994). Approximately 80% of cases are considered
screening has been performed for both the EXT1 and to be familial. Although some authors report a pene-
EXT2 genes prior to any linkage analysis. We have trance as low as 66% (Sugiura et al. 1976), more recent
screened 17 probands with the HME phenotype, for reviews tend to indicate that the condition is fully pene-
alterations in all translated exons and ﬂanking intronic trant (Hennekam 1991; Luckert-Wicklund et al. 1995).
sequences, in the EXT1 and EXT2 genes, by conforma- More than 80% of individuals with HME are diagnosed
tion-sensitive gel electrophoresis. We found the disease- during the ﬁrst decade of life (Solomon 1963). Exostoses
causing mutation in 12 families (70%), 7 (41%) of increase in size and number until closure of the growth
which have EXT1 mutations and 5 (29%) EXT2 muta- plate, at the end of puberty. The exostoses can result in
tions. Together with the previously described 1-bp dele- skeletal deformity and mild short stature or can cause
tion in exon 6, which is present in 2 of our families, we vascular or peripheral nerve compression. The most seri-
report ﬁve new mutations in EXT1. Two are missense ous complication of HME is the malignant degeneration
mutations in exon 2 (G339D and R340C), and the other of an exostosis to a chondrosarcoma or an osteosar-
three alterations (a nonsense mutation, a frameshift, and coma, which occurs in Ç2% of patients with HME
a splicing mutation) are likely to result in truncated non- (Luckert-Wicklund et al. 1995).
functional proteins. Four new mutations are described HME is genetically heterogeneous, and linkage anal-
in EXT2. A missense mutation (D227N) was found in ysis has identiﬁed at least three loci, on chromosomes
2 different families; the other three alterations (two non- 8q24.1 (EXT1; Cook et al. 1993), 11p11-p13 (EXT2;
sense mutations and one frameshift mutation) lead di- Wuyts et al. 1995), and 19p (EXT3; Le Merrer et al.
rectly or indirectly to premature stop codons. The mis- 1994; Legeai-Mallet et al. 1997). Multiple exostoses
sense mutations in EXT1 and EXT2 may pinpoint are seen in contiguous-gene syndromes mapped to
crucial domains in both proteins and therefore give clues chromosomes 8q24.1 (Langer-Giedion syndrome,
for the understanding of the pathophysiology of this MIM 150230) and 11p11-p12 (defect 11 syndrome,
skeletal disorder. MIM 601224; Bartsch et al. 1996). Sporadic exostoses
are histopathologically indistinguishable from those
seen in HME or in contiguous-gene syndromes.
Chromosome abnormalities observed in patients with
sporadic or inherited exostoses (Mertens et al. 1994;Received February 10, 1997; accepted for publication June 24,
Lu¨decke et al. 1995) and with loss of heterozygosity1997.
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generally accepted two-hit hypothesis of tumorigenesis, Genomic DNA was extracted from peripheral blood
lymphocytes, by use of the Nucleon DNA extraction kitproposed by Knudson (1971), mutation of one copy
of an EXT gene (the inherited germ-line mutation) is (Scotlab), or from buccal smears, a noninvasive tech-
nique that is more comfortable for young patients. Thisinsufﬁcient to cause the development of an exostosis. A
single chondrocyte will only become the stem cell for protocol was adapted from Bowtell (1987) and Jean-
pierre (1987). Mouth swabs were collected by the ﬁrman exostosis when its normal second EXT copy also is
inactivated by a somatic mutation. This is consistent rubbing of a cotton bud backwards and forwards be-
tween the check and gum, for 20 s (10 cotton budswith the fact that, as with other tumor–suppressor gene
syndromes, there is earlier development of exostoses in were used per individual), and were collected in a 50-
ml Falcon tube containing 5 ml of transport buffer (100inherited cases. Sarcomatous degeneration in an exosto-
sis then would require additional somatic mutation mM NaCl, 10 mM Tris, pH 8, 25 mM EDTA, pH 8,
and 0.5% SDS). The buds were incubated in transportevents in a multistep process (Hecht et al. 1997), as
illustrated by the adenoma-carcinoma sequence of carci- buffer for 2–3 h at 65C (or overnight at 37C), with
200 mg proteinase K/ml. Subsequently, guanidine HCLnogenesis in colorectal cancer (Kinzler and Vogelstein
1996). This is supported by the observation that chon- and ammonium acetate were added, to a ﬁnal concentra-
tion of 0.9 M and 0.6 M, respectively. The mix wasdrosarcomas exhibiting only LOH for chromosomes 8
and/or 11 are biologically less aggressive than tumors incubated for 1 h at 60C in a shaking incubator. Buds
then were placed inside a 20-ml syringe; the 20-ml sy-with LOH for EXT loci and for the p53 gene located at
17p13 (Raskind et al. 1995). ringe was placed into a 50-ml Falcon tube and was spun
at 1,000 rpm for 5 min, in order to dry the buds. TwoThe EXT1 and EXT2 genes recently have been cloned
by means of positional cloning strategies (Ahn et al. milliliters of cold chloroform were added, and the tubes
were shaken for 10 min, were left to stand for 1 min,1995; Stickens et al. 1996; Wuyts et al. 1996; Lu¨decke
et al. 1997), and they deﬁne a new family of related and were spun down at 2,500 rpm for 5 min. DNA was
precipitated ﬁnally with 2 vol of cold ethanol, at 020Cproteins with putative tumor-suppressor activity. A
third member of the EXT-gene family, named ‘‘EXT- over at least 2 h, and was spun down at 2,500 rpm for
30 min at 4C. The pellet was washed twice in 70%like’’ (‘‘EXT-L’’), has been identiﬁed by means of simi-
larity searches of the database for expressed sequence ethanol and was resuspended in a 500-ml buffer of 10
mM Tris and 0.1 mM EDTA.tags (dbEST) (Stickens et al. 1996) and has been mapped
to chromosome 1p36.1 (Wise et al. 1997), excluding it For the proband of each family, exons 11 and 13 and
the ﬂanking intronic regions of the EXT1 and EXT2as a candidate in EXT3-linked pedigrees.
A few reports in the literature describe mutations in genes, respectively, were PCR ampliﬁed by use of speciﬁc
primer pairs (table 1). The primer pairs for exons 2–14HME patients, either in EXT1 (Ahn et al. 1995; Raskind
et al. 1996; Hecht et al. 1997; Wells et al. 1997) or in of EXT2 were designed by use of sequences available
through GenBank (U67356–U67368). We did notEXT2 (Hogue et al. 1996; Stickens et al. 1996; Wuyts
et al. 1996), but none of them reports mutation screen- screen exons 1, 1a, and 1b, which belong to the 5 UTR
of the EXT2 gene. The PCR conditions consisted ofing of both the EXT1 and EXT2 genes simultaneously.
This study is, therefore, the ﬁrst mutation analysis of 94C for 5 min, followed by 35 cycles of 94C for 30
s, the annealing temperature (table 1) for 30 s, and 72Cisolated cases or of HME families not previously linked
to either locus, in which both the EXT1 and EXT2 genes for 30 s, and ended with a ﬁnal elongation step at 72C
for 5 min. PCR reactions were performed in an MJhave been screened for mutations. Mutation scanning
was performed by conformation-sensitive gel electro- Research PTC-225 thermal cycler. Heteroduplex analy-
sis was performed subsequently by means of CSGE anal-phoresis (CSGE), a heteroduplex method described by
Ganguly et al. (1993). In a total of 17 familial or isolated ysis, by means of a modiﬁed version of the protocol
described by Ganguly et al (1993). The 0.8 mm–thickHME cases screened, we found 7 cases (41%) with
EXT1 mutations and 5 (29%) with EXT2 mutations. gel contained 10% polyacrylamide:bis(acryoyl)pipera-
zine (99:1), 15% formamide, 10% ethylene glycol made
Subjects, Material, and Methods with a glycerol-tolerant buffer of 89 mM Tris, 7 mM
Taurine, and 0.1 mM EDTA. PCR products were heatedThe 17 families studied here were collected in the
Oxford region and are of English origin, except for fam- to 98C for 5 min, followed by incubation at 68C for
1 h, to allow formation of heteroduplexes. Samples thenily 9, which is of Philippine origin. To obtain informed
consent, we followed protocols consistent with the were subjected to electrophoresis at 500 V for 16 h at
room temperature. The gel was stained subsequentlyguidelines of the Royal College of Physicians and ap-
proved by the Central Oxford Research Ethics Commit- with ethidium bromide (1 mg/ml) for 15 min, and DNA
was visualized by UV light.tee. In ﬁgure 1, we present the pedigrees for all families
in which we found the disease-causing mutation. When a CSGE variant was detected in the proband
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Figure 1 Pedigrees of the HME families with a mutation in either the EXT1 or the EXT2 gene. Individuals with HME are indicated by blackened symbols and non-HME individuals
by unblackened symbols. Initial CSGE analysis was performed only on the proband (indicated by a ‘‘P’’) from each HME family. An asterisk (*) indicates the individuals from each pedigree
who were screened, by CSGE, for a mutation and who subsequently were analyzed at the sequence level. Individuals heterozygous for the mutation are indicated with an arrow. a, Families
with mutation in EXT1. b, Families with mutation in EXT2.
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Table 1
Primers Used to Amplify Exons from EXT1 and EXT2
Annealing Temperature/
PCR-Product Size MgCl2 Concentration
Gene, Exon, and Primera Primer Sequence (bp) (C/mM)
EXT1:
1(1):
1 Forward TGG.AAA.CTT.GGG.TGA.TTC 523 52/1.5
210 GAC.AAA.GAG.GCA.CGC.CTG
1(2):
109 GTT.ACC.AAA.ACA.TTC.TAG.CGG.C 614 58/1.5
208 CAA.GGC.TGA.CTC.CCA.AAG.AC
EXT2:
2(1):
2(1) Forward AAG.TGT.CAT.TTG.CCA.TCC.TA 436 54/1.5
2(1) Reverse TCC.ACG.TAC.TTT.TTC.AGA.GC
2(2):
2(2) Forward TGA.CTG.GAA.TGT.AGA.GAA.GC 442 53/1.5
2(2) Reverse TTC.CCT.TTA.GTT.CCC.TGA.GG
3:
3 Forward GAT.GTG.CTG.TTG.GGA.TTT.C 331 50/1.5
3 Reverse AGT.ATG.TGG.TAG.ATT.TAG.GA
4:
4 Forward GTA.ATT.CCT.GTT.CCT.CTC.CAC 283 57/1.5
4 Reverse TTG.CTT.TGA.TGC.CCA.CCA.C
5:
5 Forward TGA.AGA.CTG.GTA.AGG.AAC.AC 404 54/1.5
5 Reverse TTG.CAT.GCT.GAA.AAA.CAA.CTC
6:
6 Forward ATG.CCT.CAG.TAT.TGC.TTG.G 325 53/1.5
6 Reverse ACC.TGA.GGA.GAT.TTT.ATT.TGT.A
7:
7 Forward GAT.GTT.GTT.TCT.GCT.TGT.G 339 50/2.5
7 Reverse CAT.TAA.TTT.CCT.TTC.GTT.T
8:
8 Forward TCT.AGT.TTT.CCC.ACT.CTG.TCT.C 253 59/2.5
8 Reverse TTC.CTT.CCA.CCC.ACC.CTG.AC
9:
9 Forward GTC.AGC.CAT.ATT.GTT.ACA.GC 358 54/2.5
9 Reverse TCA.GAA.ATG.GTA.TTG.CTA.TTG.A
10:
10 Forward TCA.TGC.TTT.TAC.TAC.TTT.ATC.TC 370 56/2.5
10 Reverse CAC.CTT.TTG.GAC.TCT.ACT.GGA.
11:
11 Forward TCT.GTT.GAT.ACC.TGT.TTG.GAT.A 270 56/5
11 Reverse AAT.TGG.GTC.AAA.TAA.AAT.GTG
12:
12 Forward CTA.AAG.GGA.ACT.GCT.ATT.TTT.G 334 54/1.5
12 Reverse AAT.GTG.ACC.GCA.TCA.ATC.ATA
13:
13 Forward GCA.TGA.TTT.TAT.TGT.CCT.TGA.C 262 56/1.5
13 Reverse GAG.GTG.ACT.ATG.GCT.ACC.AG
14:
14 Forward TTG.CTG.TTA.TCT.CTC.AAC.CTC 341 56/1.5
14 Reverse CAC.CCT.TAA.CCT.ACT.ACT.CTG
NOTE.—Sequences for exons 2–11 of EXT1 are reported in the article by Wells et al. (1997).
a Since exon 1 of EXT1 and exon 2 of EXT2 are so large (963 bp and 566 bp, respectively), we used two sets of overlapping PCR primers
to screen for mutations, by CSGE.
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Table 2
Characteristics of EXT1 and EXT2 Gene Defects in Patients with Multiple Exostoses
Family Location of Mutation Mutation Consequence Name of Mutationa
Familial cases:
1 EXT1/Intron 5 TAGgtarTAGata Altered splicing 1417 (/1GrA)
2 EXT2/Exon 4 TACrTAG(TyrrStop) Nonsense Y222X
6 EXT2/Exon 4 GATrAAT (AsprAsn) Missense D227N
9 EXT1/Exon 3 TGGrTGA (TrprStop) Nonsense W374X
19 EXT2/Exon 2 TATATCrTATTATC Frameshift 77- or 78insT
21 EXT1/Exon2 GGTrGAT (GlyrAsp) Missense G339D
25 EXT2/Exon4 GATrAAT (AsprAsn) Missense D227N
36 EXT1/Exon 6 CCCCCCTGGrCCCCCCGG Frameshift 1469delTb
Isolated cases
(de novo mutations):
5 EXT1/Exon 6 CCCCCCTGGrCCCCCCGG Frameshift 1469delTb
7 EXT2/ Exon 8 CAGrTAG (GlurStop) Nonsense Q401X
13 EXT1/Exon 1 GCTTCCCGGrGCTTCCGG Frameshift 174-, 175- or 176delC
35 EXT1/Exon 2 CGCrTGC (ArgrCys) Missense R340C
a According to the nomenclature deﬁned by Beaudet and Tsui (1993). For both EXT1 and EXT2, base no. 1 corresponds to the ﬁrst base
of the initiation codon in the cDNA sequences (Ahn et al. 1995; Stickens et al. 1996; Wuyts et al. 1996).
b Already reported by Ahn et al. (1995) and by Wells et al. (1997).
(indicated in ﬁg. 1 by a ‘‘P’’), for a particular exon, a picted in ﬁgure 1. In addition to these mutations, we
also report several probable polymorphisms (table 3).second PCR reaction was performed, for all available
members (affected and unaffected; indicated in ﬁg. 1 by
EXT1 Mutationsan asterisk [*]) of the corresponding pedigree, and the PCR
A 1-bp thymidine deletion in exon 6 (1469delT) wasproducts were sequenced subsequently, without cloning in
found twice, in families 5 and 36. The ﬁve other alter-the forward and reverse orientations, with the same prim-
ations in EXT1 consisted of one frameshift mutation iners used during the PCR reaction. The PCR products were
exon 1 (174-, 175-, or 176delC; family 13), one non-puriﬁed (QIAquick PCR puriﬁcation kit; Qiagen); were
sense mutation in exon 3 (W374X; family 9), two mis-cycle sequenced, by use of dye-terminator chemistry, with
sense mutations in exon 2 (G339D in family 21 andthe AmpliTaq FS enzyme (Applied Biosystem); and were
R340C in family 35) (ﬁg. 2C), and a splice-site mutationrun on an ABI 373 DNA sequencer. The sequences were
affecting intron 5 (1417[/1GrA]; family 1) (ﬁg. 2A).analyzed visually by comparison of the mutated sequence
We examined 72 unaffected, unrelated individuals (144with a sequence from a normal control. For each family,
chromosomes), by direct sequencing of exon 2, andindividuals heterozygous for the mutation are indicated
never found the two amino acid (aa) substitutions re-with an arrow (ﬁg. 1).
ported in families 21 and 35. The GlyrAsp substitution
at position 339 changes a small neutral polar aa to an
Results acidic aa, and the R340C mutation replaces a basic aa
with a polar aa. In family 21, we only were able to
In this study, we report the results of mutation screen- obtain DNA samples for the affected individuals I-2 and
ing for the EXT1 and EXT2 genes in 17 HME families, II-1. The introduction of a Cys at position 340 poten-
of which 8 include isolated cases of HME corresponding tially allows the formation of a new disulﬁde linkage.
to de novo mutations. For a scanning method, we chose Gly at position 339 is conserved in EXT2, whereas
CSGE, a heteroduplex method, because it is easy to use Arg340 is replaced by an Ala.
and nonradioactive and because it allowed the screening
EXT2 Mutationsof up to 70 samples per gel. It is reported elsewhere that
CSGE detects 88% of mutations (Ganguly et al. 1993), Four mutations were found in EXT2. Two were non-
sense mutations (Y222X in family 2 and Q401X in fam-a sensitivity that is acceptable for this mutation analysis.
We found 7 (41%) EXT1-linked families and 5 (29%) ily 7); one was a frameshift mutation (77- or 78insT;
family 19); and a missense mutation in exon 4 was foundEXT2-linked families. Table 2 summarizes the 10 differ-
ent mutations found in 12 families, during the course in two different families (D227N; families 6 and 25)
(ﬁg. 2B). The missense mutation D227N changes anof this study, and the corresponding pedigrees are de-
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Table 3
Benign Polymorphisms of EXT1 and EXT2 Genes
Location of Name of Frequency in HME
Polymorphism Polymorphism Polymorphisma Patients (n Å 18)b
EXT1:
Exon 6 CCCrCCT (ProrPro) P477P .16
Exon 9 GAGrGAA (GlurGlu) E587E .19
EXT2:
Exon 2 CGGrAGG (ArgrArg) R10R .03
Exon 3 CrT, 84 nucleotides 537 (084CrT) .03
before the start of exon 3
a According to the nomenclature deﬁned by Beaudet and Tsui (1993). For EXT2, base no. 1 corresponds
to the ﬁrst base of the initiation codon in the cDNA sequence (Wuyts et al. 1996).
b n Å the no. of patients, or one-half the no. of alleles, tested.
acidic aa for a neutral polar aa, and it affects an aa in cated proteins. A nonmutational polymorphic stop co-
don in the human tumor suppressor gene BRCA2 hasa small domain conserved between the EXT1 and EXT2
proteins (DVSIP at positions 227–231 in the EXT2 pro- been reported (Mazoyer et al. 1996). However, this
polymorphic stop codon was located at the carboxy-tein). Direct sequencing of 120 control chromosomes
from unrelated unaffected individuals has never revealed terminal part of the BRCA2 protein, leading to a trun-
cated protein missing only 92 aa’s of a protein ofthis aa substitution at position 227.
ú3,400 aa’s. In our families, the premature stop codons
are all located in the amino-terminal part of the EXT1Discussion
or the EXT2 protein. We therefore think that it is highly
Our ﬁndings provide additional support for the EXT1 probable that these premature stop codons are the dis-
and EXT2 genes being involved in HME. However, we ease-causing mutations. In some rare cases, premature
did not ﬁnd any mutation in the EXT1 or the EXT2 gene, stop codons have been shown to induce exon skipping
in ﬁve families, but this can be explained by several rea- (Dietz et al. 1993; Gibson et al. 1993); moreover, there
sons. First, CSGE is only 88% effective (Ganguly et al. is evidence that nonsense codons reduce mRNA abun-
1993) and is unable to detect gross rearrangements, such dance (Maquat 1996), decreasing the amount of trun-
as partial or complete gene deletions or any chromosomal cated protein produced by the translational machinery.
abnormalities involving EXT1 or EXT2. Furthermore, we Of interest, the two missense mutations in exon 2 of
did not look for mutations in the promoter regions of the EXT1, found in families 21 and 35 (ﬁg. 2C), involve
EXT1 and EXT2 genes or in the 5 UTR of EXT2. Lastly, two adjacent aa’s (Gly and Arg at positions 339 and
a few families of our panel could be linked to the EXT3 340, respectively). Moreover, another aa substitution at
locus on chromosome 19 or to the EXT-L gene on chro- Arg340 (R340H) also has been reported by Raskind et
mosome 1p36. In fact, the existence of a few families in al. (1996). This strongly suggests that this region needs
which EXT1, EXT2, and EXT3 loci have been excluded to be intact, for proper functioning of the EXT1 protein.
suggests that there is another, yet-unidentiﬁed EXT locus A ProSite search revealed that the two missense muta-
responsible for HME (Hecht et al. 1997). tions in exon 2 occur in a potential 3–aa proteolysis/
The 1-bp deletion found in families 5 and 36, in exon amidation site (x-G-[RK]-[RK], in which x is the amida-
6 of EXT1, has been reported elsewhere (Ahn et al. tion site [ProSite PDOC00009]). So far, such proteoly-
1995; Wells et al., in press). This deletion immediately sis/amidation sites have been described in the C-terminal
follows a polycytosine tract, and such polypyrimidine part of the precursors of hormones and other active
tracts are known to be deletion hot spots (Lohmann et peptides, since neutral hydrophobic residues are good
al. 1994). There are two additional tracts of six cytosine substrates for the amidation site. In the EXT1 protein,
residues, in EXT1 (one in exon 1 and one in exon 6), a potential tumor suppressor, this potential proteolysis/
but they do not appear to be mutation hot spots, in our amidation site occurs in the middle of the protein, and
families. The nine other genetic alterations in EXT1 or in the amidation site consists of an Arg, a charged residue
EXT2 that are reported in this study are new mutations. that is less reactive. We cannot ﬁrmly exclude this site
The nonsense and frameshift mutations lead directly as being active in the EXT1-derived protein, although
or indirectly, respectively, to premature stop codons, this possibility is unlikely.
The EXT1 mutation found in family 1 is a splicingwhich, upon translation, may result in drastically trun-
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Figure 2 CSGE and sequence analysis of the splice-site and mis-
sense mutations reported in this study. A, Splicing defect
1417(/1GrA) at the conserved GT position of the donor splice-site
of intron 5 of EXT1, in family 1. B, D227N aa substitution located
within exon 4 of EXT2, in families 6 and 25. C, G339D and R340C
at exon 2 of EXT1, in families 21 and 35, respectively. a, CSGE
variant. b, Normal sequence. c, Sequence of the mutated allele; the
nucleotide change is underlined. For mutation D227N, the reverse
sequence obtained with primer 4R is shown, because it is easier to see
the heterozygous CrT transition. Nevertheless, the sequence obtained
with primer 4F unambiguously conﬁrms the alteration at nucleotide
681, in families 6 and 25.
mutation characterized by a 1417(/1GrA) transversion The missense mutation D227N, in exon 4 of EXT2,
was found in two different families (families 6 and 25).(ﬁg. 2A) at the conserved GT position of the donor splice
site (Nakai and Sakamoto 1994). Splice-site mutations In family 6, this mutation was found in two affected
members but not in one unaffected individual, who wascan result in one or a combination of the following types
of abnormal pre-mRNA processing: exon skipping, 15 years of age. It was not possible to obtain DNA
samples from more-distant affected members of thiscryptic splice-site usage, or intron retention. For family
1, we cannot predict the effect of the splice-site muta- multigenerational family, who live in New Zealand. The
same aa substitution also is present in family 25, but,tion, but exon skipping appears to be a more frequent
phenomenon than cryptic splice-site usage (Krawczak et surprisingly, the father, who also is heterozygous for the
GrA transversion, initially was reported as unaffected.al. 1992). In any case, the abnormal mRNA is likely to
contain a premature stop codon, therefore leading to According to several authors (Hennekam 1991; Luckert-
Wicklund et al. 1995), reduced penetrance in HME fam-the synthesis of a nonfunctional truncated protein.
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HD27981 from the NIH. A.P.M. is aWellcome Trust Principalilies remains unproven; indeed, only a very careful radio-
Research Fellow.graphical exam of individuals who are carriers of a mu-
tation in one EXT gene could rule out the presence of
small or nonpalpable exostoses in any part of the skele-
Referenceston. When we found the D227N mutation in the father
of family 25, we undertook a careful clinical examina- Ahn J, Ludecke H, Lindow S, Horton W, Lee B, Wagner M,
tion and found ﬁve tiny, but still palpable, exostoses Horsthemke B, et al (1995) Cloning of the putative tumour
(sites—both distal radii, both proximal tibiae, and the suppressor gene for hereditary multiple exostoses (EXT1).
left distal tibia). It appears, therefore, that intrafamilial Nat Genet 11:137–143
variable expressivity is likely to account for most cases Bartsch O, Wuyts W, Van Hul W, Hecht JT, Meinecke P,
Hogue D, Werner W, et al (1996) Delineation of a contigu-of clinical nonpenetrance, in HME pedigrees.
ous gene syndrome with multiple exostoses, enlarged pari-Most mutations leading to haploinsufﬁciency (non-
etal foramina, craniofacial dysostosis, and mental retarda-sense mutations, frameshifts, and altered splicing) re-
tion, caused by deletions on the short arm of chromosomeported in this study and by other groups appear to be
11. Am J Hum Genet 58:734–742private; they do not cluster in any particular region of
Beaudet A, Tsui L (1993) A suggested nomenclature for desig-the EXT1 and EXT2 genes. Nevertheless, none are lo-
nated mutations. Hum Mutat 2:245–248
cated at the extreme carboxy-terminal region of the pro- Bowtell D (1987) Rapid isolation of eukaryotic DNA. Anal
tein. This might be expected, since a protein will be Biochem 162:463–465
more severely truncated when premature termination of Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Fran-
translation occurs at the amino-terminal extremity. The comano CA, Puffenberger E, et al (1993) Genetic heteroge-
high proportion (8 of 12) of null mutations found by neity in families with hereditary multiple exostoses. Am J
Hum Genet 53:71–79our mutation analysis gives additional support to the
Dietz H, Valle D, Francomano C, Kendzior R, Pyeritz R, Cut-hypothesis that EXT genes deﬁne a new family of tumor
ting G (1993) The skipping of constitutive exons in vivosuppressor genes. Two missense mutations affecting two
induced by nonsense mutations. Science 259:680–683consecutive aa’s in exon 2 of EXT1 and one missense
Ganguly A, Rock M, Prockop D (1993) Conformation-sensi-mutation found in two different families, in exon 4 of
tive gel electrophoresis for rapid detection of single baseEXT2, seem to pinpoint crucial domains in both pro-
differences in double-stranded PCR products and DNA frag-
teins. In our series, missense mutations did not seem to ments: evidence for solvent-induced bends in DNA hetero-
cause obviously milder phenotypes, when compared duplexes. Proc Natl Acad Sci USA 90:10325–10329
with mutations leading to premature termination of Gibson R, Hajianpour A, Murer-Orlando A, Buchwald M,
translation. This would support the contention that mis- Mathew C (1993) A nonsense mutation and exon skipping
sense mutations in exon 2 of EXT1 and in exon 4 of in the Fanconi anaemia group C gene. Hum Mol Genet 2:
797–799EXT2 pinpoint crucial domains that must remain intact
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